LTR Pharma is pleased to announce that Clinical Associate Professor Darren Katz, a renowned urological surgeon and Medical Director of Men’s Health Melbourne, has joined the Company’s Scientific Advisory Board.
As Clinical Associate Professor in the Department of Surgery at the University of Melbourne, and Immediate Past Leader of the Andrology Special Advisory Group to the Urological Society of Australia and New Zealand – a position he held for six years – A/Prof Katz brings exceptional clinical expertise to advance SPONTAN® and ROXUS®, our innovative nasal spray treatments for erectile dysfunction. His appointment significantly strengthens our clinical capabilities and expands our growing prescriber networks across Australia and internationally.
A/Prof Katz completed his specialist urological training with the Royal Australasian College of Surgeons and spent two years at world-leading hospitals in New York, including Memorial Sloan-Kettering Cancer Centre and Weill-Cornell Medical Centre, where he completed sub-speciality urological fellowships. He currently directs Australia’s only Prosthetic and Microsurgical Fellowship, which attracts international urologists for advanced training, and is also a member of an Expert Clinical Advisory Group in the Department of Health in the Australian Government. His extensive front-line experience in erectile dysfunction will be invaluable as we continue to commercialise our innovative nasal spray technology.
A/Prof. Katz will join Prof. Eric Chung and Prof. Russ Chess-Williams on our established Scientific Advisory Board, who together, provide invaluable guidance as we advance the development and commercialisation of both SPONTAN® and ROXUS®.
A/Prof Darren Katz, said:
“I am excited to join LTR Pharma’s Scientific Advisory Board at this pivotal time for the Company. SPONTAN and ROXUS represent a potentially significant advancement in erectile dysfunction treatment with their rapid onset of action and safety profile. Having worked extensively with patients experiencing erectile dysfunction, I recognise the need for innovative treatments that offer greater spontaneity and fewer side effects.”